Cytokinetics to Participate in Upcoming Investor Conferences
March 06, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2023 it granted stock options to purchase an aggregate...
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
February 28, 2023 17:31 ET
|
Cytokinetics, Incorporated
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss...
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
February 24, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72nd Annual...
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
February 22, 2023 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and...
Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
February 15, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 1, 2023 at...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
January 30, 2023 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it granted stock options to purchase an aggregate...
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...